title: [Use of recombinant interleukin-2 in hemorrhagic fever with renal syndrome].
abstract: The study enrolled male patients with fever admitted to Ulyanovsk city hospital in November-December 2000 with diagnosis of hemorrhagic fever with renal syndrome (HFRS). The diagnosis was confirmed serologically. 10 patients received recombinant interleukin 2 (rIL-2) in a dose 250,000 IU/day for 5 days. rIL-2 was not given to 10 control patients. Both groups received intravenous prednisolone in a dose 90 mg/day. The response was assessed by minimal diuresis, maximal serum concentrations of urea and creatinine. No lethal outcomes occurred. Minimal diuresis was higher, creatinine and urea levels lower in patients on rIL-2 (647.0 +/- 268.6 mg/day vs 422.0 +/- 198.2 ml/day, p < 0.05; 221.8 +/- 98.1 mcmol/l vs 398.9 +/- 234.9 mcmol/l, p < 0.05; 14.9 +/- 5.1 mcmol/l vs 22.0 +/- 9.0 mmol/l, p < 0.05). Thus, it is evident that rIL-2 reduces symptoms of acute renal failure in HFRS patients. Further investigations of rIL-2 treatment in HFRS are needed.
authors.forename: A M
authors.initials: AM
authors.lastname: Shutov
authors.forename: G A
authors.initials: GA
authors.lastname: Savinova
authors.forename: L I
authors.initials: LI
authors.lastname: Kiselev
authors.forename: M N
authors.initials: MN
authors.lastname: Smirnov
authors.forename: E V
authors.initials: EV
authors.lastname: Iudintseva
mesh_terms: D000328:Adult; D005260:Female; D006480:Hemorrhagic Fever with Renal Syndrome / Q000188:drug therapy*; D006801:Humans; D007275:Injections, Intravenous; D007376:Interleukin-2 / Q000627:therapeutic use*; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use
chemical_list: D007376:Interleukin-2; D011239:Prednisolone